HemaQuest Pharmaceuticals Receives Orphan Drug Designations for Therapeutic to Treat Hemoglobin Disorders BOSTON, MA--(Marketwire - November 4, 2008) - HemaQuest Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has awarded the company orphan drug designations for sickle...

HemaQuest Announces Initiation of Phase I Clinical Trial of HQK-1001 to Treat Hemoglobin Disorders NEWTON, MA--(Marketwire - January 17, 2008) - HemaQuest Pharmaceuticals, which received its first round of venture financing three months ago, today announced that the U.S. Food and Drug...

HemaQuest Announces $20M Series A Financing for Anemia Drug Development NEWTON, MA--(Marketwire - November 1, 2007) - HemaQuest Pharmaceuticals, a new company developing proprietary small molecule therapeutics to treat serious blood disorders, today announced that it...